Guided by a team of expert leaders committed to advancing groundbreaking innovations.
Guided by a team of expert leaders committed to advancing groundbreaking innovations.
Guided by a team of
expert leaders committed to
advancing groundbreaking
innovations.
The alarming rise of bacterial resistance has intensified the search for alternatives to traditional antibiotics. One promising solution lies in the use of engineered phage lytic enzymes, developed through cutting-edge Synthetic Biology and Artificial Intelligence, to precisely target and eliminate multidrug-resistant bacteria. Our company is committed to advancing this breakthrough technology, optimizing next-generation enzybiotics to improve efficacy, stability, and precision in the ongoing battle against antimicrobial resistance.
APEXp® is a proprietary, patent- and trade-secret-protected platform that leverages synthetic biology and artificial intelligence to engineer and optimize phage lytic enzymes. This advanced technology enhances the potency, precision, and stability of next-generation enzybiotics, enabling the targeted elimination of multidrug-resistant bacteria while minimizing the risk of resistance development. APEXp® is redefining antimicrobial innovation, offering a breakthrough approach to precision-engineered alternatives to traditional antibiotics.
Within our pipeline, we have targeted programs designed to treat serious multidrug-resistant infections caused by both Gram-negative bacteria, such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as well as Gram-positive pathogens. These programs focus on developing innovative solutions to address the growing challenge of antimicrobial resistance across a broad spectrum of harmful bacteria.
